drugset

drugset / Trial / NCT00393146

A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

NCT00393146 ↗

Phase 2 Completed 57 enrolled GlaxoSmithKline

RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to look at the safety, tolerability and effectiveness of 28 days of dosing of GW856553 in rheumatoid arthritis patients.

Timeline

Start: 2006-10
Primary completion: 2008-01
Completion: 2008-01

Publications

Yang S, Lukey P, Beerahee M, Hoke F. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases. Clin Pharmacokinet. 2013 Mar;52(3):187-98. doi: 10.1007/s40262-012-0025-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Losmapimod	Small molecule	7.5 mg	Oral

Indications